WebJan 18, 2024 · Between July 26, 2015, and Aug 30, 2024, 292 patients were randomly assigned, 197 to the ramucirumab group and 95 to the placebo group. ... et al. External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: a multicenter cohort study. ... Ann Oncol. 2024; (published online June 26.) … WebOh WK, Miao R, Vekeman F, et al. Real-world characteristics and outcomes of patients with metastatic castration-resistant prostate cancer receiving chemotherapy versus androgen …
Chemoradiation, surgery and adjuvant chemotherapy …
WebBackground: We evaluated the efficacy and safety of S-1 plus oxaliplatin (SOX) as an alternative to cisplatin plus S-1 (CS) in first-line chemotherapy for advanced gastric … WebWe conducted network meta-analysis based on a random-effects consistency model as described by White et al 13 following a multivariate metaregression approach to pool evidence from direct and indirect comparisons. In addition, consistency between indirect and direct comparisons was evaluated. ... Ann Oncol. 2015;26(3):477-485. doi:10.1093 ... glass companies greeley co
Impact of age and medical comorbidity on adjuvant …
WebAug 31, 2015 · FOLFOXIRI plus bevacizumab is a feasible treatment option for those patients who meet the inclusion criteria of the present study, irrespective of baseline clinical characteristics and RAS or BRAF mutational status. WebFeb 7, 2024 · Zhou C, Wu YL, Chen G. et al. Final overall survival results from a randomised, Phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol 2015; 26: 1877–1883. [Google Scholar] WebCheah et al. Ann. Oncol. 2015;26:1175-79. 4. Martin et al. Blood. 2016;127:1559-63. 5. Dreyling et al. Lancet. 2016;387:770-8. 6. Epperla et al. Hematol. Oncol. 2024;35:528 … g0 g1 g2 # optimizer parameter groups